BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 10906146)

  • 1. Cdk2-dependent phosphorylation and functional inactivation of the pRB-related p130 protein in pRB(-), p16INK4A(+) tumor cells.
    Cheng L; Rossi F; Fang W; Mori T; Cobrinik D
    J Biol Chem; 2000 Sep; 275(39):30317-25. PubMed ID: 10906146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and activity of the retinoblastoma protein (pRB)-family proteins, p107 and p130, during L6 myoblast differentiation.
    Kiess M; Gill RM; Hamel PA
    Cell Growth Differ; 1995 Oct; 6(10):1287-98. PubMed ID: 8845306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential regulation of retinoblastoma tumor suppressor protein by G(1) cyclin-dependent kinase complexes in vivo.
    Ezhevsky SA; Ho A; Becker-Hapak M; Davis PK; Dowdy SF
    Mol Cell Biol; 2001 Jul; 21(14):4773-84. PubMed ID: 11416152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The E2F-family proteins induce distinct cell cycle regulatory factors in p16-arrested, U343 astrocytoma cells.
    Dirks PB; Rutka JT; Hubbard SL; Mondal S; Hamel PA
    Oncogene; 1998 Aug; 17(7):867-76. PubMed ID: 9780003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. E2F/p107 and E2F/p130 complexes are regulated by C/EBPalpha in 3T3-L1 adipocytes.
    Timchenko NA; Wilde M; Iakova P; Albrecht JH; Darlington GJ
    Nucleic Acids Res; 1999 Sep; 27(17):3621-30. PubMed ID: 10446255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence.
    Carroll JS; Prall OW; Musgrove EA; Sutherland RL
    J Biol Chem; 2000 Dec; 275(49):38221-9. PubMed ID: 10991938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p130 and p107 use a conserved domain to inhibit cellular cyclin-dependent kinase activity.
    Woo MS; Sánchez I; Dynlacht BD
    Mol Cell Biol; 1997 Jul; 17(7):3566-79. PubMed ID: 9199292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. E1A modulates phosphorylation of p130 and p107 by differentially regulating the activity of G1/S cyclin/CDK complexes.
    Parreño M; Garriga J; Limón A; Albrecht JH; Graña X
    Oncogene; 2001 Aug; 20(35):4793-806. PubMed ID: 11521191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins.
    Sangfelt O; Erickson S; Castro J; Heiden T; Gustafsson A; Einhorn S; Grandér D
    Oncogene; 1999 May; 18(18):2798-810. PubMed ID: 10362250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cancer preventive flavonoid silibinin causes hypophosphorylation of Rb/p107 and Rb2/p130 via modulation of cell cycle regulators in human prostate carcinoma DU145 cells.
    Tyagi A; Agarwal C; Agarwal R
    Cell Cycle; 2002; 1(2):137-42. PubMed ID: 12429923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes.
    Lundberg AS; Weinberg RA
    Mol Cell Biol; 1998 Feb; 18(2):753-61. PubMed ID: 9447971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclin E and c-Myc promote cell proliferation in the presence of p16INK4a and of hypophosphorylated retinoblastoma family proteins.
    Alevizopoulos K; Vlach J; Hennecke S; Amati B
    EMBO J; 1997 Sep; 16(17):5322-33. PubMed ID: 9311992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points.
    Mateyak MK; Obaya AJ; Sedivy JM
    Mol Cell Biol; 1999 Jul; 19(7):4672-83. PubMed ID: 10373516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melanin accumulation accelerates melanocyte senescence by a mechanism involving p16INK4a/CDK4/pRB and E2F1.
    Bandyopadhyay D; Medrano EE
    Ann N Y Acad Sci; 2000 Jun; 908():71-84. PubMed ID: 10911949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inducible pRb2/p130 expression and growth-suppressive mechanisms: evidence of a pRb2/p130, p27Kip1, and cyclin E negative feedback regulatory loop.
    Howard CM; Claudio PP; De Luca A; Stiegler P; Jori FP; Safdar NM; Caputi M; Khalili K; Giordano A
    Cancer Res; 2000 May; 60(10):2737-44. PubMed ID: 10825149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function.
    Foster JS; Henley DC; Bukovsky A; Seth P; Wimalasena J
    Mol Cell Biol; 2001 Feb; 21(3):794-810. PubMed ID: 11154267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Site-directed mutant p21 proteins defective in both inhibition of E2F-regulated transcription and disruption of E2F-p130-cyclin-cdk2 complexes.
    Robles SJ; Shiyanov P; Aristodemo GT; Raychaudhuri P; Adami GR
    DNA Cell Biol; 1998 Jan; 17(1):9-18. PubMed ID: 9468218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D:Cdk4/6 complexes results in active pRb.
    Ezhevsky SA; Nagahara H; Vocero-Akbani AM; Gius DR; Wei MC; Dowdy SF
    Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10699-704. PubMed ID: 9380698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. pRB and p107 have distinct effects when expressed in pRB-deficient tumor cells at physiologically relevant levels.
    Jiang H; Karnezis AN; Tao M; Guida PM; Zhu L
    Oncogene; 2000 Aug; 19(34):3878-87. PubMed ID: 10951581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The interactions of E2F with pRB and with p107 are regulated via the phosphorylation of pRB and p107 by a cyclin-dependent kinase.
    Suzuki-Takahashi I; Kitagawa M; Saijo M; Higashi H; Ogino H; Matsumoto H; Taya Y; Nishimura S; Okuyama A
    Oncogene; 1995 May; 10(9):1691-8. PubMed ID: 7753545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.